This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

F. T. Fraunfelder, MD
Oregon Health Sciences University Portland

Ralph Edwards, MD
World Health Organization Uppsala, Sweden

JAMA. 1995;273(10):773-774.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Leuprolide acetate (Lupron Depo, Lupron Injection, TAP Pharmaceuticals Inc, Deerfield, Ill) is a gonadotropin-releasing hormone used to control endometriosis or advanced prostatic cancer. To our knowledge, this is the first overview of possible adverse ocular events occurring in patients receiving this drug. Cases were received from TAP

Pharmaceuticals Inc, the World Health Organization Collaborating Center for International Drug Monitoring, Uppsala, Sweden (which instigated this review), and the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Portland, Ore.

The most common adverse ocular event possibly associated with leuprolide acetate is blurred vision, with or without headaches and/or dizziness (Table). This may occur after each injection or as late as the sixth injection, as in one patient. Transitory blurred vision may occur shortly after the injection, usually lasting 1 to 2 hours, but in rare instances may continue for 2 to 3 weeks. This may be a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?